Trial Profile
Efficacy, safety and tolerability of interferon beta-1b in patients with in juvenile patients with relapsing-remitting multiple sclerosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 May 2017
Price :
$35
*
At a glance
- Drugs Interferon beta-1b (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms BETAPAEDIC
- 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology
- 17 Sep 2016 Results (2 years) presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 13 Oct 2010 New trial record